Konjac glucosylceramides

1. Konjac glucosylceramides improve WAIS-IV Coding performance in humans.

   Human trialsubjective decline in memory or cognitive function3.6 mg/day24 weeksn = 40

   Effects of Konjac glucosylceramides on cognitive function in cognitively unimpaired older adults with subjective cognitive concerns: a randomized, double-blind, controlled pilot study · The journal of nutrition, health & aging · 9 Sep 2026

1. Konjac glucosylceramides are associated with plasma amyloid-β composite biomarker in humans.

   Human triallow baseline amyloid burden5.4 mg/day24 weeksn = 40

   Effects of Konjac glucosylceramides on cognitive function in cognitively unimpaired older adults with subjective cognitive concerns: a randomized, double-blind, controlled pilot study · The journal of nutrition, health & aging · 9 Sep 2026

Plasma amyloid-β composite biomarker →